Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anbenitamab repodatecan + capecitabine + enlonstobart + anbenitamab
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JSKN003 + capecitabine + SG001 + KN026 is an investigational combination regimen being evaluated for the first-line treatment of HER2-positive advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma. The regimen combines two HER2-targeted agents developed by Alphamab Oncology—JSKN003 (anbenitamab repodatecan), a biparatopic HER2-targeting antibody-drug conjugate (ADC) carrying a topoisomerase I inhibitor payload, and KN026 (anbenitamab), a bispecific antibody targeting two distinct HER2 epitopes—with the anti-PD-1 monoclonal antibody enlonstobart (SG001) and the oral chemotherapeutic prodrug capecitabine. By simultaneously targeting multiple HER2 epitopes, delivering a cytotoxic payload, blocking the PD-1/PD-L1 immune checkpoint, and inhibiting DNA synthesis, this multi-pronged regimen aims to overcome resistance and enhance anti-tumor efficacy. In a Phase II clinical trial, this combination (Cohort B) demonstrated a 100% objective response rate (ORR) in patients with first-line HER2-positive GC/GEJ.
- Other names
- JSKN003 + capecitabine + enlonstobart + anbenitamabJSKN003 + capecitabine + enlonstobart + KN026JSKN003 + capecitabine + SG001 + anbenitamabJSKN003 + capecitabine + SG001 + KN026anbenitamab repodatecan + capecitabine + enlonstobart + KN026anbenitamab repodatecan + capecitabine + SG001 + anbenitamabanbenitamab repodatecan + capecitabine + SG001 + KN026
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on anbenitamab repodatecan + capecitabine + enlonstobart + anbenitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anbenitamab repodatecan + capecitabine + enlonstobart + anbenitamab.